Financial Commitments Group capital expenditure relating to property, plant and equipment contracted but not provided for amountedto$27m 2007$5m.
Under the Groups acquisition and joint development agreements with NUCRYST Pharmaceuticals Corp. amounts of up to $8m 2007 $8m could become payable on achievement of certain milestones related to regulatory and reimbursement approvals with a further $20m 2007 $20m contingent on achievement ofsales milestones.
As part of the Groups acquisition of BlueSky Medical Group Inc. a further $55m 2007 $55m could become payable on achievement of sales milestones.
This is in addition to the milestones that management considers probable that have been recognised in the acquisition cost at their present fair value see Note 32 .
The Group is contractually committed to four milestone payments, whichtotal $60m 2007 $60m, related to the US approval and commercialisation of DUROLANE which may become payable under the terms of the agreement .
